MX366171B - Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina. - Google Patents

Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.

Info

Publication number
MX366171B
MX366171B MX2015006333A MX2015006333A MX366171B MX 366171 B MX366171 B MX 366171B MX 2015006333 A MX2015006333 A MX 2015006333A MX 2015006333 A MX2015006333 A MX 2015006333A MX 366171 B MX366171 B MX 366171B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
melanocortin
receptor
selective agonists
formula
Prior art date
Application number
MX2015006333A
Other languages
English (en)
Other versions
MX2015006333A (es
Inventor
A Abdel-Malek Zalfa
Koikov Leonid
J Knittel James
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of MX2015006333A publication Critical patent/MX2015006333A/es
Publication of MX366171B publication Critical patent/MX366171B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a los tri- y tetrapéptidos cortos de acuerdo con la siguiente Fórmula I Ar (CH2) mX1-X2-CO-X3-X4-X5-(Trp) n-NX6R son agonistas, selectivos, potentes del receptor de melanocortina 1 (MC1R). Se proporcionan en la presente composiciones farmacéuticas que incluyen los agonistas de péptido de la Fórmula I de MC1R y métodos para tratar enfermedades de la piel.
MX2015006333A 2012-11-21 2013-11-20 Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina. MX366171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729018P 2012-11-21 2012-11-21
PCT/US2013/071033 WO2014081846A2 (en) 2012-11-21 2013-11-20 Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor

Publications (2)

Publication Number Publication Date
MX2015006333A MX2015006333A (es) 2016-01-20
MX366171B true MX366171B (es) 2019-07-01

Family

ID=50776668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006333A MX366171B (es) 2012-11-21 2013-11-20 Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.
MX2015006342A MX365620B (es) 2012-11-21 2013-11-20 Composiciones para el cuidado de la piel y metodos que comprenden agonistas selectivos del receptor de melanocortina 1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015006342A MX365620B (es) 2012-11-21 2013-11-20 Composiciones para el cuidado de la piel y metodos que comprenden agonistas selectivos del receptor de melanocortina 1.

Country Status (7)

Country Link
US (3) US9434764B2 (es)
EP (2) EP2925340B8 (es)
AU (3) AU2013348044B2 (es)
CA (2) CA2892144C (es)
ES (2) ES2768423T3 (es)
MX (2) MX366171B (es)
WO (2) WO2014081845A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187264A1 (en) * 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
EP3411012A4 (en) 2016-02-04 2019-08-28 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE
CN109803979B (zh) 2016-10-04 2023-01-31 帝斯曼知识产权资产管理有限公司 黑皮质素-1-受体激动剂
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
CN111278846B (zh) * 2017-10-30 2023-10-27 帝斯曼知识产权资产管理有限公司 抗微生物四肽
PL3758730T3 (pl) * 2018-02-27 2023-03-20 Lipotrue, S.L. Peptydy i kompozycje do stosowania w kosmetyce i medycynie
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
KR20230016008A (ko) * 2020-06-10 2023-01-31 미쓰비시 타나베 파마 코퍼레이션 광선성 피부질환의 예방 또는 치료제
CN116925182A (zh) * 2022-04-02 2023-10-24 肽鼎生物科技(深圳)有限公司 多肽药物及凝胶制剂的应用
EP4385515A1 (en) * 2022-12-16 2024-06-19 Bella Aurora Labs, S.A. Composition for skin repigmentation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536295A (ja) * 1998-12-14 2002-10-29 パラチン テクノロジーズ, インク. 金属ペプチド組合せライブラリ及びその利用法
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
EP1441750A4 (en) * 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
DK1689349T3 (da) 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
CA2582607C (en) 2004-10-08 2016-07-12 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
AU2008310530A1 (en) * 2007-10-12 2009-04-16 Decode Genetics Ehf Sequence variants for inferring human pigmentation patterns
CA2998948A1 (en) 2008-05-27 2009-12-17 Genzyme Corporation Peptide analogs of alpha-melanocyte stimulating hormone
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−1受容体特異的環状ペプチド

Also Published As

Publication number Publication date
WO2014081845A2 (en) 2014-05-30
AU2013348044B2 (en) 2018-03-15
ES2768423T3 (es) 2020-06-22
AU2018204153A1 (en) 2018-06-28
US20150297667A1 (en) 2015-10-22
WO2014081845A3 (en) 2015-07-30
CA2892134C (en) 2022-10-04
AU2013348043B2 (en) 2017-11-02
AU2013348043A1 (en) 2015-06-04
EP2925340B8 (en) 2019-07-24
US10301355B2 (en) 2019-05-28
ES2738555T3 (es) 2020-01-23
MX2015006333A (es) 2016-01-20
EP2925340A4 (en) 2017-01-04
US9434764B2 (en) 2016-09-06
EP2922565A4 (en) 2016-06-15
AU2018204153B2 (en) 2019-04-18
WO2014081846A3 (en) 2015-11-19
EP2922565A2 (en) 2015-09-30
AU2013348044A1 (en) 2015-06-04
WO2014081846A2 (en) 2014-05-30
CA2892134A1 (en) 2014-05-30
EP2925340B1 (en) 2019-05-08
US20150299251A1 (en) 2015-10-22
EP2925340A2 (en) 2015-10-07
US20180066016A1 (en) 2018-03-08
US9834580B2 (en) 2017-12-05
CA2892144C (en) 2020-04-28
MX365620B (es) 2019-06-07
EP2922565B1 (en) 2019-11-13
CA2892144A1 (en) 2014-05-30
MX2015006342A (es) 2016-02-25

Similar Documents

Publication Publication Date Title
MX366171B (es) Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina.
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
PH12012500756A1 (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
IN2012DN06720A (es)
MX2013001272A (es) Nuevo tratamiento del carcinoma de prostata.
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
MX2015011498A (es) Peptidos para el rejuvenecimiento de la piel y metodos de uso de los mismos.
MX2018006299A (es) Analogos de peptido de la hormona de estimulacion de alfa-melanocito.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
NZ702392A (en) Compositions and methods for cancer immunotherapy
SG10201907684PA (en) Androgen receptor modulator and uses thereof
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
EP3818991A3 (en) Compositions and methods for treating diseases
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
WO2015081306A3 (en) Peptide tyrosinase activators
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.

Legal Events

Date Code Title Description
FG Grant or registration